Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Current Quarter	$-0.6	Next Quarter	$-0.59
Current Year	$-2.09	Next Year	$-1.53
QoQ Growth	+1.7%	YoY Growth	+26.8%
3Y EPS CAGR	-49.9%	Target Price	$8.00
Consensus	Buy	Upside	+34.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVIR	$5.95	-0.42%	273.58K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVIR	$5.95	-0.4%	273.58K
3
4
5
6

AVIR

AVIR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Atea Pharmaceuticals Inc. Data in Excel

Get Atea Pharmaceuticals Inc. Data in Excel